Lawrence B. Cohen’s Albany Molecular Research Inc AMRI Stock Holding History

Lawrence B. Cohen’s Portfolio AMRI Stock Details AMRI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-24,875	Closed	-$540K	–	75
2017 Q2	$540K	Sell	24,875 -12,675	-34%	-$230K	0.35%	49
2017 Q1	$527K	Hold	37,550	–	–	0.32%	52
2016 Q4	$704K	Buy	37,550 +1,502	+4%	+$25.5K	0.43%	46
2016 Q3	$595K	Hold	36,048	–	–	0.35%	49
2016 Q2	$484K	Buy	36,048 +4,048	+13%	+$59.1K	0.29%	54
2016 Q1	$489K	Hold	32,000	–	–	0.32%	50
2015 Q4	$635K	Hold	32,000	–	–	0.43%	42
2015 Q3	$557K	Hold	32,000	–	–	0.39%	42
2015 Q2	$647K	Buy	32,000 +10,325	+48%	+$199K	0.41%	40
2015 Q1	$381K	Hold	21,675	–	–	0.23%	57
2014 Q4	$353K	Hold	21,675	–	–	0.21%	60
2014 Q3	$478K	Hold	21,675	–	–	0.32%	49
2014 Q2	$436K	Hold	21,675	–	–	0.29%	48
2014 Q1	$403K	Hold	21,675	–	–	0.28%	47
2013 Q4	$218K	Hold	21,675	–	–	0.16%	65
2013 Q3	$279K	Hold	21,675	–	–	0.21%	55
2013 Q2	$257K	Buy	+21,675	New	+$235K	0.19%	58

Other funds holding AMRI

Ancora Advisors Cleveland, Ohio $4.7B AUM 19.05% 1-Year Est. Return

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

Lawrence B. Cohen's AMRI Position: Q3 2017 in Review

Lawrence B. Cohen sold out of Albany Molecular Research Inc (AMRI) in Q3 2017, closing a stake of 24,875 shares — an estimated $540K sold.

Lawrence B. Cohen first reported a position in AMRI in Q2 2013 and held it in 17 quarters. The position peaked at $704K in Q4 2016. 2 funds tracked by Wall St. Rank hold AMRI as of Q3 2017.

Lawrence B. Cohen reported no remaining Albany Molecular Research Inc position as of Q3 2017 after selling out during the quarter.
Lawrence B. Cohen sold 24,875 Albany Molecular Research Inc shares in Q3 2017, an estimated $540K.
Lawrence B. Cohen first reported a position in Albany Molecular Research Inc in Q2 2013 and held it in 17 quarters.
Lawrence B. Cohen's Albany Molecular Research Inc position peaked at $704K in Q4 2016.
2 funds tracked by Wall St. Rank held Albany Molecular Research Inc as of Q3 2017.

Based on Lawrence B. Cohen's 13F filing for Q3 2017, filed 3 Nov 2017.